DiabetesHypoArrhythmiaNCT02778269
Predicting Hypoglycaemia and Arrhythmias in the Patient With Diabetes and CKD - Validation Study
A study testing 12-lead ECG T-shirt and Dexcom G4-System in people with Diabetes and Hypoglycaemia, run by RWTH Aachen University at 1 site in Germany.
Trial summary
Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD). Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Diabetes, Hypoglycaemia, Chronic Kidney Disease
- What is being tested?
- 12-lead ECG T-shirt and Dexcom G4-System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 7 participants
- Where
- 1 siteGermany
- Study dates
- Jun 2016to Mar 2017
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Insulin-treated diabetes mellitus (type 1 or 2)
- CKD with eGFR < 45 ml/min, determined using the Modification of Diet in Renal Disease (MDRD) formula
- Stable anti-diabetic and cardiac medication prior to inclusion
- Male aged ≥ 18 years
- Written informed consent prior to study participation
- Adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel.
Who cannot join
- Pregnancy or women without sufficient contraception, adapted specifically to amenorrhoeic hemodialysis patients
- Life expectancy below 6 months
- Participation in another clinical trial within the previous 2 months
- History of any other illness, which, in the opinion of the investigator, might pose an unacceptable risk when administering study medication
- Any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study
- Alcohol or drug abuse
Show all 11Show fewer
- Patient has been committed to an institution by legal or regulatory order
- Patients with any kind of pacemakers
- Expected non-compliance
- Patients unwilling or unable to give informed consent, or with limited ability to comply with instructions for this study
- Participation in a parallel interventional clinical trial
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease - Validation Study
Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD). Various studies have shown that hypoglycemic episodes are strong predictors of cardiovascular mortality in both type 1 and type 2 diabetic patients. Experimental data and small clinical studies link hypoglycemia with ECG changes and SCD, but little is known about the direct association of hypoglycemic events and/or rapid swings in blood glucose with arrhythmias in this high risk population. Ideally, an algorithm should help to identify patients at risk for hypoglycemia-associated arrhythmias and SCD, but hitherto systematic analyses of blood glucose values and 12-channel ECGs are lacking in these patients.
In this validation study a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device wich can record long-term 12-lead ECG data will be tested. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes involving disadvantages like severe direct side effects on the skin such as rash and bullous lesions as well as slipping electrodes. By the means of the proposed ECG T-shirt those drawbacks will be avoided.
Read the detailed description
Patients with diabetes mellitus (DM), especially those with a long duration of diabetes, insulin treatment and chronic kidney disease (CKD) are vulnerable patients exhibiting a high risk for cardiac arrhythmias and sudden cardiac death (SCD). Various factors such as the presence of coronary heart disease, diabetic cardiomyopathy as well autonomic neuropathy are underlying pathologies associated with the development of potentially fatal arrhythmias in these patients while hypoglycemic events are considered to directly trigger these arrhythmias. It has been postulated that severe hypoglycemia may lead to cardiac arrhythmias, later summarized as the "dead in bed" syndrome. In addition, recent data from large cardiovascular outcome trials in patients with type 2 diabetes suggest that severe hypoglycemia is associated with an increased risk of cardiovascular events and cardiovascular related death. Moreover, CKD markedly increases the risk for hypoglycemia and even a moderate impairment of kidney function (eGFR < 45 ml/min) is associated with a significant increase in SCD.
Various pathophysiological mechanisms may contribute to the increased cardiovascular mortality after hypoglycemia including hypoglycemia-induced release of catecholamines, pro-arrhythmogenic ECG alterations as well as inflammatory changes. Morphological and functional alterations of the heart occurring in CKD further contribute to these mechanisms. So far performed studies were limited by a short duration of glucose and ECG monitoring and by the fact that only 3 lead Holter-ECGs were used, thus not allowing the assessment of more sophisticated ECG abnormalities such as QT dispersion, T-wave alternans, or late potentials. Therefore no clear data exist to predict arrhythmias and SCD and its relation to hypoglycemia in patients with diabetes. Ideally, a SCD risk score could identify and characterize high-risk patients but to date little is known about hypoglycemia-associated ECG markers for the identification of patients at risk for arrhythmias and SCD.
In the general population, various ECG risk markers for SCD have been identified such as heart rate, cardiac rhythm abnormalities, atrioventriculare (AV) block, QT length, QT dispersion, heart-rate variability (HRV), T-wave alternans, late potentials, as well as left- (LBBB) or right-bundle branch block (RBBB) (reviewed in). In patients with diabetes hypoglycemia, diabetic cardiomyopathy, as well as the presence of autonomic neuropathy may lead to such ECG abnormalities. Merely sparse data exist on the effect of spontaneous hypoglycemic episodes and changes in ECG parameters with only a small study in patients with type 1 diabetes demonstrating that nocturnal hypoglycemia is associated with a decrease in the low-frequency component of heart rate variability. To date, more sophisticated markers such as QT dispersion, late potentials, or T-wave alternans were not examined in a "real-life setting", most likely because these markers require a 12 lead ECG registration of longer duration.
However, for the establishment of a risk algorithm for the prediction of hypoglycemia-associated arrhythmias it is mandatory to perform long duration simultaneous glucose monitoring and 12 lead ECG registration to capture these ECG risk markers for SCD.
In an actually running project the investigators are evaluating the association of hypoglycemic events/glucose swings and arrhythmias/ECG predictors for SCD a clinical study will be performed in 50 patients with insulin-treated diabetes and moderate to severe CKD. These patients receive 7 days continuous glucose and ECG registration and data will be used for the development of the risk assessment model.
The current validation study seeks to confirm the risk assessment model developed in collaboration with AICES - Aachen Institute for Advanced Study in Computational Engineering Science and to approve the capacitive ECG registration device obtained in collaboration with Philips Chair for Medical Information Technology at University Clinical Center Aachen (UKA). To this end, 10 patients with insulin-treated diabetes and moderate to severe CKD will be included. Seven day glucose monitoring as well as data of capacitive ECG recordings will be generated in this study, thus allowing validation and adjustment of the developed medical hardware and the mathematic models. The study item is a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device. The device can record long-term 12-lead ECG data. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes, which are hardly tolerated by the patients because of severe direct side effects on the skin such as rash and bullous lesions. These side effects are a result of skin preparation and electrode gel. The proposed ECG T-shirt does not need these problematic preparations. Another benefit is the fixed placement of the electrodes on the T-shirt. In regular 12-lead ECG long-term recordings, the electrodes may fall off and the patient needs to reattach them. Therefore, faulty positioning of the electrodes may occur.
- Conditions
- Diabetes, Hypoglycaemia, Chronic Kidney Disease
- Being tested
- 12-lead ECG T-shirt, Dexcom G4-System
- Keywords
- ECG, CGM, Hypoglycaemia, Sudden Cardiac Death
- Medical subject headings
- Diabetes Mellitus, Hypoglycemia, Renal Insufficiency, Chronic, Death, Sudden, Cardiac
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
12-lead ECG T-shirtDevice
The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
Dexcom G4-SystemDevice
Also called CGM
Continuous Glucose Monitoring
| Study group | Role | What they receive |
|---|---|---|
| Study Treatment | Experimental | The patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System. Receives: Device: 12-lead ECG T-shirt; Device: Dexcom G4-System |
What is being measured
The primary outcome is the main question the study is designed to answer.
QRS duration [sec]
Prolonged duration indicates e.g. hyperkalemia or bundle branch block.
Measured: 7 days
QRS amplitude [mV]
Increased amplitude indicates cardiac hypertrophy.
Measured: 7 days
Ventricular activation time (VAT) [sec]
Measured in increased QRS amplitude.
Measured: 7 days
Number of power-line interference on the ECG
Feasibility of the 12-lead ECG T-shirt: movements of the t-shirt might cause power-line interferences on the ECG.
Measured: 7 days
Secondary outcomes (1)
Number of congruences concerning identified arrhythmias of this validation study and the previous study "Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease".
The number of congruences of this validation study and the previous study will validate the developed mathematic risk assessment model.
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 May 2016 (estimated)
- Study startJun 2016
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 7 participants (actual)
Sponsor and investigators
- Lead sponsor
- RWTH Aachen University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Nikolaus Marx, Prof. Dr., Principal investigator, Uniklinik RWTH Aachen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02778269
- Sponsor's protocol ID
- 14-030 MPG
- Acronym
- HypoArrhythmia
- Status last verified
- Aug 2016
- First submitted
- 9 May 2016
- Last updated
- 7 Apr 2017
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis. 1997 Aug;30(2 Suppl 1):S107-17. No abstract available.
PubMed 9259696Carrero JJ, de Mutsert R, Axelsson J, Dekkers OM, Jager KJ, Boeschoten EW, Krediet RT, Dekker FW; NECOSAD Study Group. Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011 Jan;26(1):270-6. doi: 10.1093/ndt/gfq386. Epub 2010 Jul 9.
PubMed 20621930Tattersall RB. Brittle diabetes revisited: the Third Arnold Bloom Memorial Lecture. Diabet Med. 1997 Feb;14(2):99-110. doi: 10.1002/(SICI)1096-9136(199702)14:23.0.CO;2-I.
PubMed 9047086Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia. 2009 Jan;52(1):42-5. doi: 10.1007/s00125-008-1177-7. Epub 2008 Oct 30.
PubMed 18972096Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. 2014 Jan;100(1):21-7. doi: 10.1136/heartjnl-2013-303871. Epub 2013 May 22.
PubMed 23697655Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011 Mar;7(3):145-54. doi: 10.1038/nrneph.2010.191. Epub 2011 Feb 1.
PubMed 21283136Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013 Sep 21;12:135. doi: 10.1186/1475-2840-12-135.
PubMed 24053606Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci. 2013 Apr;1281(1):36-50. doi: 10.1111/nyas.12044. Epub 2013 Feb 6.
PubMed 23387439Schachinger H, Port J, Brody S, Linder L, Wilhelm FH, Huber PR, Cox D, Keller U. Increased high-frequency heart rate variability during insulin-induced hypoglycaemia in healthy humans. Clin Sci (Lond). 2004 Jun;106(6):583-8. doi: 10.1042/CS20030337.
PubMed 14717655Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999 Sep;246(3):299-307. doi: 10.1046/j.1365-2796.1999.00528.x.
PubMed 10475998Koivikko ML, Karsikas M, Salmela PI, Tapanainen JS, Ruokonen A, Seppanen T, Huikuri HV, Perkiomaki JS. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia. 2008 Mar;51(3):426-35. doi: 10.1007/s00125-007-0902-y. Epub 2007 Dec 19.
PubMed 18097646Junttila MJ, Castellanos A, Huikuri HV, Myerburg RJ. Risk markers of sudden cardiac death in standard 12-lead electrocardiograms. Ann Med. 2012 Nov;44(7):717-32. doi: 10.3109/07853890.2011.594807. Epub 2011 Jul 11.
PubMed 21745092Robinson RT, Harris ND, Ireland RH, Lee S, Newman C, Heller SR. Mechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia. Diabetes. 2003 Jun;52(6):1469-74. doi: 10.2337/diabetes.52.6.1469.
PubMed 12765959Koivikko ML, Tulppo MP, Kiviniemi AM, Kallio MA, Perkiomaki JS, Salmela PI, Airaksinen KE, Huikuri HV. Autonomic cardiac regulation during spontaneous nocturnal hypoglycemia in patients with type 1 diabetes. Diabetes Care. 2012 Jul;35(7):1585-90. doi: 10.2337/dc11-2120. Epub 2012 May 18.
PubMed 22611064
Study at a glance
From the registry record, last updated by the sponsor on 7 Apr 2017. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Predicting Hypoglycaemia and Arrhythmias in the Vulnerable Patient With Diabetes and Chronic Kidney Disease - Validation Study
- ClinicalTrials.gov ID
- NCT02778269
- Acronym / sponsor ID
- HypoArrhythmia / 14-030 MPG
- Conditions
- Diabetes, Hypoglycaemia, Chronic Kidney Disease
- Keywords
- ECG, CGM, Hypoglycaemia, Sudden Cardiac Death
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 7 participants (actual)
- Lead sponsor
- RWTH Aachen UniversityUniversity, hospital or other
- Study start
- Jun 2016 (actual)
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 19 May 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Patients with insulin-dependent diabetes mellitus (DM) and chronic kidney disease (CKD) exhibit an excessive risk for cardiac arrhythmias, in particular sudden cardiac death (SCD). Various studies have shown that hypoglycemic episodes are strong predictors of cardiovascular mortality in both type 1 and type 2 diabetic patients. Experimental data and small clinical studies link hypoglycemia with ECG changes and SCD, but little is known about the direct association of hypoglycemic events and/or rapid swings in blood glucose with arrhythmias in this high risk population. Ideally, an algorithm should help to identify patients at risk for hypoglycemia-associated arrhythmias and SCD, but hitherto systematic analyses of blood glucose values and 12-channel ECGs are lacking in these patients.
In this validation study a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device wich can record long-term 12-lead ECG data will be tested. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes involving disadvantages like severe direct side effects on the skin such as rash and bullous lesions as well as slipping electrodes. By the means of the proposed ECG T-shirt those drawbacks will be avoided.
Detailed description
Patients with diabetes mellitus (DM), especially those with a long duration of diabetes, insulin treatment and chronic kidney disease (CKD) are vulnerable patients exhibiting a high risk for cardiac arrhythmias and sudden cardiac death (SCD). Various factors such as the presence of coronary heart disease, diabetic cardiomyopathy as well autonomic neuropathy are underlying pathologies associated with the development of potentially fatal arrhythmias in these patients while hypoglycemic events are considered to directly trigger these arrhythmias. It has been postulated that severe hypoglycemia may lead to cardiac arrhythmias, later summarized as the "dead in bed" syndrome. In addition, recent data from large cardiovascular outcome trials in patients with type 2 diabetes suggest that severe hypoglycemia is associated with an increased risk of cardiovascular events and cardiovascular related death. Moreover, CKD markedly increases the risk for hypoglycemia and even a moderate impairment of kidney function (eGFR < 45 ml/min) is associated with a significant increase in SCD.
Various pathophysiological mechanisms may contribute to the increased cardiovascular mortality after hypoglycemia including hypoglycemia-induced release of catecholamines, pro-arrhythmogenic ECG alterations as well as inflammatory changes. Morphological and functional alterations of the heart occurring in CKD further contribute to these mechanisms. So far performed studies were limited by a short duration of glucose and ECG monitoring and by the fact that only 3 lead Holter-ECGs were used, thus not allowing the assessment of more sophisticated ECG abnormalities such as QT dispersion, T-wave alternans, or late potentials. Therefore no clear data exist to predict arrhythmias and SCD and its relation to hypoglycemia in patients with diabetes. Ideally, a SCD risk score could identify and characterize high-risk patients but to date little is known about hypoglycemia-associated ECG markers for the identification of patients at risk for arrhythmias and SCD.
In the general population, various ECG risk markers for SCD have been identified such as heart rate, cardiac rhythm abnormalities, atrioventriculare (AV) block, QT length, QT dispersion, heart-rate variability (HRV), T-wave alternans, late potentials, as well as left- (LBBB) or right-bundle branch block (RBBB) (reviewed in). In patients with diabetes hypoglycemia, diabetic cardiomyopathy, as well as the presence of autonomic neuropathy may lead to such ECG abnormalities. Merely sparse data exist on the effect of spontaneous hypoglycemic episodes and changes in ECG parameters with only a small study in patients with type 1 diabetes demonstrating that nocturnal hypoglycemia is associated with a decrease in the low-frequency component of heart rate variability. To date, more sophisticated markers such as QT dispersion, late potentials, or T-wave alternans were not examined in a "real-life setting", most likely because these markers require a 12 lead ECG registration of longer duration.
However, for the establishment of a risk algorithm for the prediction of hypoglycemia-associated arrhythmias it is mandatory to perform long duration simultaneous glucose monitoring and 12 lead ECG registration to capture these ECG risk markers for SCD.
In an actually running project the investigators are evaluating the association of hypoglycemic events/glucose swings and arrhythmias/ECG predictors for SCD a clinical study will be performed in 50 patients with insulin-treated diabetes and moderate to severe CKD. These patients receive 7 days continuous glucose and ECG registration and data will be used for the development of the risk assessment model.
The current validation study seeks to confirm the risk assessment model developed in collaboration with AICES - Aachen Institute for Advanced Study in Computational Engineering Science and to approve the capacitive ECG registration device obtained in collaboration with Philips Chair for Medical Information Technology at University Clinical Center Aachen (UKA). To this end, 10 patients with insulin-treated diabetes and moderate to severe CKD will be included. Seven day glucose monitoring as well as data of capacitive ECG recordings will be generated in this study, thus allowing validation and adjustment of the developed medical hardware and the mathematic models. The study item is a 12-lead ECG T-shirt consisting of textile electrodes and a data logging device. The device can record long-term 12-lead ECG data. The purpose of the T-shirt is to improve the patient's comfort for long-term recordings and to prevent adverse effects of regular ECG electrodes. Current systems are limited by the use of ECG electrodes, which are hardly tolerated by the patients because of severe direct side effects on the skin such as rash and bullous lesions. These side effects are a result of skin preparation and electrode gel. The proposed ECG T-shirt does not need these problematic preparations. Another benefit is the fixed placement of the electrodes on the T-shirt. In regular 12-lead ECG long-term recordings, the electrodes may fall off and the patient needs to reattach them. Therefore, faulty positioning of the electrodes may occur.
Study design
- Primary purpose
- Prevention
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study Treatment | Experimental | Device: 12-lead ECG T-shirt, Device: Dexcom G4-SystemThe patients wear a 12-lead ECG T-shirt for 7 days. During this time period ECG data are measured continuously. In addition the continous glucose monitoring system (CGM) records glucose levels via Dexcom G4-System. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Insulin-treated diabetes mellitus (type 1 or 2)
- CKD with eGFR < 45 ml/min, determined using the Modification of Diet in Renal Disease (MDRD) formula
- Stable anti-diabetic and cardiac medication prior to inclusion
- Male aged ≥ 18 years
- Written informed consent prior to study participation
Key exclusion criteria (11 listed)
- Pregnancy or women without sufficient contraception, adapted specifically to amenorrhoeic hemodialysis patients
- Life expectancy below 6 months
- Participation in another clinical trial within the previous 2 months
- History of any other illness, which, in the opinion of the investigator, might pose an unacceptable risk when administering study medication
- Any current or past medical condition and/or required medication to treat a condition that could affect the evaluation of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 12-lead ECG T-shirtThe 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches. | Device | Study Treatment |
| Dexcom G4-SystemAlso: CGMContinuous Glucose Monitoring | Device | Study Treatment |
Primary outcome
QRS duration [sec]
Time frame: 7 days
Prolonged duration indicates e.g. hyperkalemia or bundle branch block.
QRS amplitude [mV]
Time frame: 7 days
Increased amplitude indicates cardiac hypertrophy.
Ventricular activation time (VAT) [sec]
Time frame: 7 days
Measured in increased QRS amplitude.
Number of power-line interference on the ECG
Time frame: 7 days
Feasibility of the 12-lead ECG T-shirt: movements of the t-shirt might cause power-line interferences on the ECG.
1 secondary outcome
Number of congruences concerning identified arrhythmias of this validation study and the previous study "Predicting Hypoglycaemia and Arrhythmias in the vulnerable Patient with Diabetes and Chronic Kidney Disease".
Time frame: 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 Apr 2017.
- Background: PubMed 9259696Causes of death. USRDS. United States Renal Data System. Am J Kidney Dis. 1997 Aug;30(2 Suppl 1):S107-17. No abstract available.
- Background: PubMed 20621930Carrero JJ, de Mutsert R, Axelsson J, Dekkers OM, Jager KJ, Boeschoten EW, Krediet RT, Dekker FW; NECOSAD Study Group. Sex differences in the impact of diabetes on mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011 Jan;26(1):270-6. doi: 10.1093/ndt/gfq386. Epub 2010 Jul 9.
- Background: PubMed 9047086Tattersall RB. Brittle diabetes revisited: the Third Arnold Bloom Memorial Lecture. Diabet Med. 1997 Feb;14(2):99-110. doi: 10.1002/(SICI)1096-9136(199702)14:23.0.CO;2-I.
- Background: PubMed 18972096Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. Diabetologia. 2009 Jan;52(1):42-5. doi: 10.1007/s00125-008-1177-7. Epub 2008 Oct 30.
- Background: PubMed 23697655Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? Heart. 2014 Jan;100(1):21-7. doi: 10.1136/heartjnl-2013-303871. Epub 2013 May 22.
- Background: PubMed 21283136Shamseddin MK, Parfrey PS. Sudden cardiac death in chronic kidney disease: epidemiology and prevention. Nat Rev Nephrol. 2011 Mar;7(3):145-54. doi: 10.1038/nrneph.2010.191. Epub 2011 Feb 1.
- Background: PubMed 24053606Hanefeld M, Duetting E, Bramlage P. Cardiac implications of hypoglycaemia in patients with diabetes - a systematic review. Cardiovasc Diabetol. 2013 Sep 21;12:135. doi: 10.1186/1475-2840-12-135.
- Background: PubMed 23387439Giorgino F, Leonardini A, Laviola L. Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials. Ann N Y Acad Sci. 2013 Apr;1281(1):36-50. doi: 10.1111/nyas.12044. Epub 2013 Feb 6.
- Background: PubMed 14717655Schachinger H, Port J, Brody S, Linder L, Wilhelm FH, Huber PR, Cox D, Keller U. Increased high-frequency heart rate variability during insulin-induced hypoglycaemia in healthy humans. Clin Sci (Lond). 2004 Jun;106(6):583-8. doi: 10.1042/CS20030337.
- Background: PubMed 10475998Landstedt-Hallin L, Englund A, Adamson U, Lins PE. Increased QT dispersion during hypoglycaemia in patients with type 2 diabetes mellitus. J Intern Med. 1999 Sep;246(3):299-307. doi: 10.1046/j.1365-2796.1999.00528.x.
- Background: PubMed 18097646Koivikko ML, Karsikas M, Salmela PI, Tapanainen JS, Ruokonen A, Seppanen T, Huikuri HV, Perkiomaki JS. Effects of controlled hypoglycaemia on cardiac repolarisation in patients with type 1 diabetes. Diabetologia. 2008 Mar;51(3):426-35. doi: 10.1007/s00125-007-0902-y. Epub 2007 Dec 19.
- Background: PubMed 21745092Junttila MJ, Castellanos A, Huikuri HV, Myerburg RJ. Risk markers of sudden cardiac death in standard 12-lead electrocardiograms. Ann Med. 2012 Nov;44(7):717-32. doi: 10.3109/07853890.2011.594807. Epub 2011 Jul 11.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nikolaus Marx, Prof. Dr. principal investigator
Uniklinik RWTH Aachen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 12-lead ECG T-shirt and Dexcom G4-System in people with Diabetes and Hypoglycaemia, run by RWTH Aachen University at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 7 Apr 2017. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
QRS duration [sec] (time frame: 7 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02778269, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Apr 2017.